STOCK TITAN

[8-K] Volcon, Inc. Common stock Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Supernus has completed its cash/CVR acquisition of Sage Therapeutics (SAGE). The tender offer, priced at $8.50 per share in cash plus one contingent value right (CVR) worth up to an additional $3.50, expired at one minute past 11:59 p.m. ET on 30 Jul 2025 and was not extended. Equiniti Trust Company, acting as depositary, reported that 36,313,509 shares—approximately 58 % of Sage’s outstanding common stock—were validly tendered and not withdrawn, satisfying the offer’s minimum condition. All tendered shares were irrevocably accepted for payment and will be settled promptly in accordance with the Merger Agreement.

On 31 Jul 2025, immediately after the offer closing, Purchaser was merged into Sage under DGCL §251(h), making Sage a wholly owned subsidiary of Supernus. As a consequence, Sage’s common stock will be delisted from the Nasdaq Global Market and deregistered under the Exchange Act.

  • Tender consideration: $8.50 cash + CVR (up to $3.50).
  • Shares tendered: 36.3 M (≈58 % of total outstanding).
  • Offer expiration: 30 Jul 2025; merger completion: 31 Jul 2025.

All other disclosures in the original Schedule 14D-9 remain unchanged.

Supernus ha completato l'acquisizione in contanti/CVR di Sage Therapeutics (SAGE). L'offerta pubblica di acquisto, fissata a 8,50 dollari per azione in contanti più un diritto di valore contingente (CVR) del valore massimo aggiuntivo di 3,50 dollari, è scaduta alle 00:01 ET del 30 luglio 2025 senza essere prorogata. Equiniti Trust Company, in qualità di depositario, ha riportato che 36.313.509 azioni – circa il 58% del capitale sociale ordinario di Sage – sono state validamente presentate e non ritirate, soddisfacendo la condizione minima dell'offerta. Tutte le azioni presentate sono state irrevocabilmente accettate per il pagamento e saranno liquidate tempestivamente secondo quanto previsto dall'Accordo di Fusione.

Il 31 luglio 2025, immediatamente dopo la chiusura dell'offerta, l'Acquirente è stato fuso in Sage ai sensi della DGCL §251(h), rendendo Sage una controllata interamente posseduta da Supernus. Di conseguenza, le azioni ordinarie di Sage saranno ritirate dalla quotazione al Nasdaq Global Market e cancellate dalla registrazione ai sensi dell'Exchange Act.

  • Considerazione dell'offerta: 8,50 $ in contanti + CVR (fino a 3,50 $).
  • Azioni presentate: 36,3 milioni (circa il 58% del totale in circolazione).
  • Scadenza dell'offerta: 30 luglio 2025; completamento fusione: 31 luglio 2025.

Tutte le altre comunicazioni contenute nel modulo originale Schedule 14D-9 restano invariate.

Supernus ha completado la adquisición en efectivo/CVR de Sage Therapeutics (SAGE). La oferta pública de adquisición, valorada en 8,50 dólares por acción en efectivo más un derecho contingente de valor (CVR) por hasta 3,50 dólares adicionales, expiró a la 1:01 a.m. ET del 30 de julio de 2025 y no fue extendida. Equiniti Trust Company, actuando como depositario, informó que 36.313.509 acciones — aproximadamente el 58 % del capital social ordinario de Sage — fueron válidamente presentadas y no retiradas, cumpliendo la condición mínima de la oferta. Todas las acciones presentadas fueron irrevocablemente aceptadas para pago y se liquidarán prontamente conforme al Acuerdo de Fusión.

El 31 de julio de 2025, inmediatamente después del cierre de la oferta, el Comprador se fusionó con Sage bajo DGCL §251(h), convirtiendo a Sage en una subsidiaria de propiedad total de Supernus. Como consecuencia, las acciones ordinarias de Sage serán retiradas de la cotización en Nasdaq Global Market y dadas de baja bajo la Exchange Act.

  • Consideración de la oferta: 8,50 $ en efectivo + CVR (hasta 3,50 $).
  • Acciones presentadas: 36,3 millones (aproximadamente el 58 % del total en circulación).
  • Vencimiento de la oferta: 30 de julio de 2025; finalización de la fusión: 31 de julio de 2025.

Las demás divulgaciones en el Schedule 14D-9 original permanecen sin cambios.

Supernus가 Sage Therapeutics(SAGE)에 대한 현금/CVR 인수를 완료했습니다. 주당 8.50달러 현금과 최대 3.50달러 추가 가치가 있는 조건부 가치 권리(CVR) 1개를 포함한 공개매수는 2025년 7월 30일 동부시간 기준 오후 11시 59분 1분 후에 만료되었으며 연장되지 않았습니다. 예치기관인 Equiniti Trust Company는 Sage의 발행 보통주 약 58%에 해당하는 36,313,509주가 유효하게 제출되고 철회되지 않았음을 보고했으며, 이는 공개매수의 최소 조건을 충족합니다. 제출된 모든 주식은 취소 불가능하게 인수되어 지급이 즉시 이루어질 예정이며 합병 계약에 따라 신속히 정산됩니다.

2025년 7월 31일, 공개매수 종료 직후 매수자는 DGCL §251(h)에 따라 Sage와 합병되어 Sage는 Supernus의 100% 자회사로 편입됩니다. 그 결과, Sage의 보통주는 나스닥 글로벌 마켓에서 상장 폐지되고 증권거래법에 따라 등록이 말소됩니다.

  • 공개매수 대가: 주당 8.50달러 현금 + CVR(최대 3.50달러).
  • 제출된 주식 수: 3,630만 주 (총 발행 주식의 약 58%).
  • 공개매수 만료일: 2025년 7월 30일; 합병 완료일: 2025년 7월 31일.

원본 Schedule 14D-9의 기타 공시는 변경되지 않았습니다.

Supernus a finalisé son acquisition en espèces/CVR de Sage Therapeutics (SAGE). L'offre publique d'achat, fixée à 8,50 $ par action en espèces plus un droit de valeur conditionnelle (CVR) pouvant valoir jusqu'à 3,50 $ supplémentaires, a expiré à 00h01 ET le 30 juillet 2025 sans prolongation. Equiniti Trust Company, agissant en tant que dépositaire, a rapporté que 36 313 509 actions – soit environ 58 % des actions ordinaires en circulation de Sage – ont été valablement déposées et non retirées, satisfaisant ainsi à la condition minimale de l'offre. Toutes les actions déposées ont été irrévocablement acceptées pour paiement et seront réglées rapidement conformément à l'accord de fusion.

Le 31 juillet 2025, immédiatement après la clôture de l'offre, l'Acheteur a été fusionné avec Sage conformément à la DGCL §251(h), faisant de Sage une filiale à 100 % détenue par Supernus. Par conséquent, les actions ordinaires de Sage seront retirées de la cote du Nasdaq Global Market et radiées en vertu de l'Exchange Act.

  • Contrepartie de l'offre : 8,50 $ en espèces + CVR (jusqu'à 3,50 $).
  • Actions déposées : 36,3 millions (environ 58 % du total en circulation).
  • Expiration de l'offre : 30 juillet 2025 ; finalisation de la fusion : 31 juillet 2025.

Toutes les autres divulgations du Schedule 14D-9 original restent inchangées.

Supernus hat die Bar-/CVR-Übernahme von Sage Therapeutics (SAGE) abgeschlossen. Das Übernahmeangebot, bewertet mit 8,50 USD pro Aktie in bar plus einem bedingten Wertrecht (CVR) im Wert von bis zu weiteren 3,50 USD, lief am 30. Juli 2025 um 00:01 Uhr ET ab und wurde nicht verlängert. Die Equiniti Trust Company, als Depotbank, berichtete, dass 36.313.509 Aktien – etwa 58 % des ausstehenden Stammkapitals von Sage – gültig eingereicht und nicht zurückgezogen wurden, womit die Mindestbedingung des Angebots erfüllt ist. Alle eingereichten Aktien wurden unwiderruflich zur Zahlung angenommen und werden gemäß der Fusionsvereinbarung umgehend abgewickelt.

Am 31. Juli 2025, unmittelbar nach Schließung des Angebots, wurde der Käufer gemäß DGCL §251(h) mit Sage verschmolzen, wodurch Sage eine hundertprozentige Tochtergesellschaft von Supernus wurde. Folglich werden die Stammaktien von Sage vom Nasdaq Global Market delistet und gemäß dem Exchange Act abgemeldet.

  • Übernahmeangebot: 8,50 USD in bar + CVR (bis zu 3,50 USD).
  • Eingereichte Aktien: 36,3 Mio. (ca. 58 % des Gesamtbestands).
  • Ablauf des Angebots: 30. Juli 2025; Abschluss der Fusion: 31. Juli 2025.

Alle weiteren Angaben im ursprünglichen Schedule 14D-9 bleiben unverändert.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Offer closed, merger executed, cash & CVR consideration now locked in—transaction risk removed.

The amendment confirms successful completion of the Supernus-Sage deal. With 58 % of shares tendered, the minimum acceptance threshold was met, enabling a swift §251(h) back-end merger. This extinguishes residual execution risk and establishes a definitive payout timeline for shareholders. The delisting notice eliminates future market liquidity but is routine for a squeeze-out. From an arbitrage perspective, the filing converts the position from event-driven to cash-settled plus CVR optionality; focus shifts to milestone probabilities embedded in the CVR.

TL;DR: Outcome is largely neutral—price known, shares delist; only CVR upside remains.

The filing finalises an already-priced takeover, delivering an $8.50 cash exit and potential future CVR value. Public shareholders lose ongoing exposure and liquidity as SAGE leaves Nasdaq, a negative for those preferring standalone biopharma upside. However, closure eliminates headline risk and releases capital. The CVR’s undisclosed milestones represent the only residual equity-like participation.

Supernus ha completato l'acquisizione in contanti/CVR di Sage Therapeutics (SAGE). L'offerta pubblica di acquisto, fissata a 8,50 dollari per azione in contanti più un diritto di valore contingente (CVR) del valore massimo aggiuntivo di 3,50 dollari, è scaduta alle 00:01 ET del 30 luglio 2025 senza essere prorogata. Equiniti Trust Company, in qualità di depositario, ha riportato che 36.313.509 azioni – circa il 58% del capitale sociale ordinario di Sage – sono state validamente presentate e non ritirate, soddisfacendo la condizione minima dell'offerta. Tutte le azioni presentate sono state irrevocabilmente accettate per il pagamento e saranno liquidate tempestivamente secondo quanto previsto dall'Accordo di Fusione.

Il 31 luglio 2025, immediatamente dopo la chiusura dell'offerta, l'Acquirente è stato fuso in Sage ai sensi della DGCL §251(h), rendendo Sage una controllata interamente posseduta da Supernus. Di conseguenza, le azioni ordinarie di Sage saranno ritirate dalla quotazione al Nasdaq Global Market e cancellate dalla registrazione ai sensi dell'Exchange Act.

  • Considerazione dell'offerta: 8,50 $ in contanti + CVR (fino a 3,50 $).
  • Azioni presentate: 36,3 milioni (circa il 58% del totale in circolazione).
  • Scadenza dell'offerta: 30 luglio 2025; completamento fusione: 31 luglio 2025.

Tutte le altre comunicazioni contenute nel modulo originale Schedule 14D-9 restano invariate.

Supernus ha completado la adquisición en efectivo/CVR de Sage Therapeutics (SAGE). La oferta pública de adquisición, valorada en 8,50 dólares por acción en efectivo más un derecho contingente de valor (CVR) por hasta 3,50 dólares adicionales, expiró a la 1:01 a.m. ET del 30 de julio de 2025 y no fue extendida. Equiniti Trust Company, actuando como depositario, informó que 36.313.509 acciones — aproximadamente el 58 % del capital social ordinario de Sage — fueron válidamente presentadas y no retiradas, cumpliendo la condición mínima de la oferta. Todas las acciones presentadas fueron irrevocablemente aceptadas para pago y se liquidarán prontamente conforme al Acuerdo de Fusión.

El 31 de julio de 2025, inmediatamente después del cierre de la oferta, el Comprador se fusionó con Sage bajo DGCL §251(h), convirtiendo a Sage en una subsidiaria de propiedad total de Supernus. Como consecuencia, las acciones ordinarias de Sage serán retiradas de la cotización en Nasdaq Global Market y dadas de baja bajo la Exchange Act.

  • Consideración de la oferta: 8,50 $ en efectivo + CVR (hasta 3,50 $).
  • Acciones presentadas: 36,3 millones (aproximadamente el 58 % del total en circulación).
  • Vencimiento de la oferta: 30 de julio de 2025; finalización de la fusión: 31 de julio de 2025.

Las demás divulgaciones en el Schedule 14D-9 original permanecen sin cambios.

Supernus가 Sage Therapeutics(SAGE)에 대한 현금/CVR 인수를 완료했습니다. 주당 8.50달러 현금과 최대 3.50달러 추가 가치가 있는 조건부 가치 권리(CVR) 1개를 포함한 공개매수는 2025년 7월 30일 동부시간 기준 오후 11시 59분 1분 후에 만료되었으며 연장되지 않았습니다. 예치기관인 Equiniti Trust Company는 Sage의 발행 보통주 약 58%에 해당하는 36,313,509주가 유효하게 제출되고 철회되지 않았음을 보고했으며, 이는 공개매수의 최소 조건을 충족합니다. 제출된 모든 주식은 취소 불가능하게 인수되어 지급이 즉시 이루어질 예정이며 합병 계약에 따라 신속히 정산됩니다.

2025년 7월 31일, 공개매수 종료 직후 매수자는 DGCL §251(h)에 따라 Sage와 합병되어 Sage는 Supernus의 100% 자회사로 편입됩니다. 그 결과, Sage의 보통주는 나스닥 글로벌 마켓에서 상장 폐지되고 증권거래법에 따라 등록이 말소됩니다.

  • 공개매수 대가: 주당 8.50달러 현금 + CVR(최대 3.50달러).
  • 제출된 주식 수: 3,630만 주 (총 발행 주식의 약 58%).
  • 공개매수 만료일: 2025년 7월 30일; 합병 완료일: 2025년 7월 31일.

원본 Schedule 14D-9의 기타 공시는 변경되지 않았습니다.

Supernus a finalisé son acquisition en espèces/CVR de Sage Therapeutics (SAGE). L'offre publique d'achat, fixée à 8,50 $ par action en espèces plus un droit de valeur conditionnelle (CVR) pouvant valoir jusqu'à 3,50 $ supplémentaires, a expiré à 00h01 ET le 30 juillet 2025 sans prolongation. Equiniti Trust Company, agissant en tant que dépositaire, a rapporté que 36 313 509 actions – soit environ 58 % des actions ordinaires en circulation de Sage – ont été valablement déposées et non retirées, satisfaisant ainsi à la condition minimale de l'offre. Toutes les actions déposées ont été irrévocablement acceptées pour paiement et seront réglées rapidement conformément à l'accord de fusion.

Le 31 juillet 2025, immédiatement après la clôture de l'offre, l'Acheteur a été fusionné avec Sage conformément à la DGCL §251(h), faisant de Sage une filiale à 100 % détenue par Supernus. Par conséquent, les actions ordinaires de Sage seront retirées de la cote du Nasdaq Global Market et radiées en vertu de l'Exchange Act.

  • Contrepartie de l'offre : 8,50 $ en espèces + CVR (jusqu'à 3,50 $).
  • Actions déposées : 36,3 millions (environ 58 % du total en circulation).
  • Expiration de l'offre : 30 juillet 2025 ; finalisation de la fusion : 31 juillet 2025.

Toutes les autres divulgations du Schedule 14D-9 original restent inchangées.

Supernus hat die Bar-/CVR-Übernahme von Sage Therapeutics (SAGE) abgeschlossen. Das Übernahmeangebot, bewertet mit 8,50 USD pro Aktie in bar plus einem bedingten Wertrecht (CVR) im Wert von bis zu weiteren 3,50 USD, lief am 30. Juli 2025 um 00:01 Uhr ET ab und wurde nicht verlängert. Die Equiniti Trust Company, als Depotbank, berichtete, dass 36.313.509 Aktien – etwa 58 % des ausstehenden Stammkapitals von Sage – gültig eingereicht und nicht zurückgezogen wurden, womit die Mindestbedingung des Angebots erfüllt ist. Alle eingereichten Aktien wurden unwiderruflich zur Zahlung angenommen und werden gemäß der Fusionsvereinbarung umgehend abgewickelt.

Am 31. Juli 2025, unmittelbar nach Schließung des Angebots, wurde der Käufer gemäß DGCL §251(h) mit Sage verschmolzen, wodurch Sage eine hundertprozentige Tochtergesellschaft von Supernus wurde. Folglich werden die Stammaktien von Sage vom Nasdaq Global Market delistet und gemäß dem Exchange Act abgemeldet.

  • Übernahmeangebot: 8,50 USD in bar + CVR (bis zu 3,50 USD).
  • Eingereichte Aktien: 36,3 Mio. (ca. 58 % des Gesamtbestands).
  • Ablauf des Angebots: 30. Juli 2025; Abschluss der Fusion: 31. Juli 2025.

Alle weiteren Angaben im ursprünglichen Schedule 14D-9 bleiben unverändert.

false 0001829794 0001829794 2025-07-31 2025-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________

 

FORM 8-K

__________________________

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 31, 2025 (July 31, 2025)

__________________________

 

Empery Digital, Inc.

(Exact Name of Registrant as Specified in its Charter)

__________________________

 

Delaware 001-40867 84-4882689

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

 

3121 Eagles Nest Street, Suite 120

Round Rock, TX 78665

(Address of principal executive offices and zip code)

 

(512) 400-4271

(Registrant’s telephone number, including area code)

 

Volcon, Inc.

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.00001 per share   EMPD   NASDAQ

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

   

 

 

Item 7.01 Regulation FD Disclosure.

 

On July 31, 2025, Empery Digital, Inc. (the “Company”) issued a press release providing an update regarding the Company’s current Bitcoin holdings and the Company’ corporate name change and ticker symbol change.

 

The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

 

Item 8.01 Other Information.

 

As previously disclosed, on July 28, 2025, the Company filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company. to change the name of the Company from “Volcon, Inc.” to “Empery Digital, Inc.” In connection with the Name Change, effective as of market open on July 31, 2025, the Company’s common stock, par value $0.00001 per share (the “Common Stock”) began trading under the Company’s new ticker symbol “EMPD” on The Nasdaq Capital Market. The CUSIP of the Common Stock did not change in connection with the ticker symbol change.

 

Since the last update on July 28th, 2025, the Company has acquired an additional 303.04 BTC for a total purchase price of $35.6 million. The Company currently holds 3,803.23 BTC acquired for an aggregate purchase price of approximately $448 million, reflecting an average purchase price of $117,706 per BTC.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated July 31, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

 2 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  EMPERY DIGITAL, INC.
   
   
Date: July 31, 2025 /s/ Greg Endo
  Greg Endo
Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

Volcon Inc

NASDAQ:VLCN

VLCN Rankings

VLCN Latest News

VLCN Latest SEC Filings

VLCN Stock Data

475.21M
44.75M
0.7%
2.16%
16.36%
Auto Manufacturers
Motor Vehicles & Passenger Car Bodies
Link
United States
ROUND ROCK